Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9. Epub 2007 Apr 23.

PMID:
17452630
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.

PMID:
19055754
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
[PubMed - indexed for MEDLINE]
4.

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.

PMID:
19261849
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.

Am J Pathol. 2010 Oct;177(4):1647-56. doi: 10.2353/ajpath.2010.090885. Epub 2010 Sep 2.

PMID:
20813970
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.

Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK.

Breast Cancer Res. 2011;13(6):R125. doi: 10.1186/bcr3071. Epub 2011 Dec 1.

PMID:
22132754
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F.

Mol Cancer Ther. 2011 Jun;10(6):1093-101. doi: 10.1158/1535-7163.MCT-10-1089. Epub 2011 Apr 13.

PMID:
21490305
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.

Rogers HA, Mayne C, Chapman RJ, Kilday JP, Coyle B, Grundy RG.

Clin Cancer Res. 2013 Dec 1;19(23):6450-60. doi: 10.1158/1078-0432.CCR-13-0222. Epub 2013 Sep 27.

PMID:
24077346
[PubMed - indexed for MEDLINE]
9.

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.

Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 Mar 1;19(5):1094-105. doi: 10.1158/1078-0432.CCR-12-3039. Epub 2013 Jan 14.

PMID:
23319822
[PubMed - indexed for MEDLINE]
Free Article
10.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.

PMID:
21594665
[PubMed - indexed for MEDLINE]
11.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.

PMID:
17936563
[PubMed - indexed for MEDLINE]
Free Article
12.

PI3K/AKT pathway activation in bladder carcinogenesis.

Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.

Int J Cancer. 2014 Apr 15;134(8):1776-84. doi: 10.1002/ijc.28518. Epub 2013 Oct 24.

PMID:
24122582
[PubMed - indexed for MEDLINE]
13.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

PMID:
23136191
[PubMed - indexed for MEDLINE]
Free Article
14.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

PMID:
22090358
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

PMID:
23538402
[PubMed - indexed for MEDLINE]
Free Article
16.

Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.

Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH.

Clin Cancer Res. 2013 Dec 15;19(24):6830-41. doi: 10.1158/1078-0432.CCR-13-0624. Epub 2013 Oct 16.

PMID:
24132918
[PubMed - indexed for MEDLINE]
17.

Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T.

Mol Cell Biol. 2007 Jan;27(2):662-77. Epub 2006 Oct 23.

PMID:
17060456
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F.

Cancer Res. 2008 Oct 1;68(19):8127-36. doi: 10.1158/0008-5472.CAN-08-0755.

PMID:
18829572
[PubMed - indexed for MEDLINE]
Free Article
19.

TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.

Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, Lai JM.

Oncogene. 2012 May 10;31(19):2389-400. doi: 10.1038/onc.2011.419. Epub 2011 Sep 26.

PMID:
21996732
[PubMed - indexed for MEDLINE]
20.

[Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].

Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.

Zhonghua Bing Li Xue Za Zhi. 2011 Dec;40(12):799-804. Chinese.

PMID:
22336203
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk